Irvine, CA – May 28, 2026 – Johnson & Johnson has received CE mark approvals for CEREGLIDE™ 42 and CEREGLIDE™ 57. Together with CEREGLIDE™ 71 and INNERGLIDE™ 7 delivery aid, these additions expand Johnson & Johnson MedTech Stroke Solutions Portfolio in EMEA.
“We designed this multi-axial system to address procedural challenges physicians face when treating stroke,” said Christian Cuzick, Worldwide President, Neurovascular, MedTech, Johnson & Johnson. “With this expanded portfolio, we’re simplifying decisions, enhancing consistency across device sizes, and reinforcing our commitment to helping improve patient outcomes.”
“With the addition of CEREGLIDE 42, CEREGLIDE 57 and INNERGLIDE 7, we complete our aspiration portfolio and provide physicians with a comprehensive solution across varied anatomies and clot locations. Grounded in our heritage of stroke and clot science, and complemented by EMBOTRAP™ III and NIMBUS™, this portfolio reinforces our commitment to helping clinicians optimize outcomes for patients with stroke,” said Alistair Stewart, Business Unit Head, EMEA, Neurovascular.
The CEREGLIDE 42 and CEREGLIDE 57 Aspiration Catheters (CEREGLIDE 42/57) are single-lumen, variable stiffness catheters. Each catheter has a hydrophilic coating to improve lubricity during navigation and includes a radiopaque marker on the distal tip for fluoroscopic visualization.
The CEREGLIDE 71 Aspiration System is composed of the CEREGLIDE 71 Aspiration Catheter and the INNERGLIDE 7 Delivery Aid. The CEREGLIDE 71 Catheter is a single lumen variable stiffness catheter that features a hydrophilic coating to improve lubricity during navigation and a radiopaque marker at the distal tip to enable fluoroscopic visualization. The INNERGLIDE 7 Delivery Aid is a single lumen catheter with a tapered tip, hydrophilic coating for increased lubricity, a radiopaque tip for fluoroscopic visualization and a proximal luer hub. The Delivery Aid is designed to facilitate delivery of the CEREGLIDE 71 catheter to selected neurovascular vessels.
The CEREGLIDE family of catheters now includes 42, 57, 71, and 92 aspiration catheters, providing a range of sizes to support aspiration during mechanical thrombectomy and to promote procedural consistency and device compatibility.
Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more information, visit jnjmedtech.com/en-EMEA and connect on LinkedIn and @JNJMedTech
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopedics, surgery and vision solutions at thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to the CEREGLIDE™ 42, CEREGLIDE™ 57, and INNERGLIDE™ 7. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at sec.gov, jnj.com, investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Important information: Prior to use, refer to the instructions for use for indications, contraindications, adverse events, warnings and precautions.
Media contact:
Teresa Maria Frei
[email protected]
This product can only be used by healthcare professionals in EMEA.
EM_NEU_ISCH_415248
(c) Johnson & Johnson and its affiliates 2026